Company: PCRX
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001396814-25-000061
Chunk: 97

Company: Pacira BioSciences, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 97
---
31, 2025ReturnsAllowancesPromptPaymentDiscountsServiceFeesVolumeRebates andChargebacksGovernmentRebatesTotalBalance at December 31, 2024$1,600 $1,308 $4,875 $4,863 $1,707 $14,353 Provision225 3,384 5,223 35,003 1,094 44,929 Payments(150)(3,276)(6,080)(36,149)(1,403)(47,058)Balance at March 31, 2025$1,675 $1,416 $4,018 $3,717 $1,398 $12,224 

Pacira BioSciences, Inc.  |  Q1 2025 Form 10-Q  |  Page 42

March 31, 2024ReturnsAllowancesPromptPaymentDiscountsServiceFeesVolumeRebates andChargebacksGovernmentRebatesTotalBalance at December 31, 2023$1,868 $1,308 $3,697 $5,870 $1,175 $13,918 Provision76 3,057 4,771 25,800 636 34,340 Payments(175)(3,087)(5,064)(26,320)(333)(34,979)Balance at March 31, 2024$1,769 $1,278 $3,404 $5,350 $1,478 $13,279 

Total reductions of gross product sales from sales-related allowances and accruals were $44.9 million and $34.3 million, or 21.1% and 17.1% of gross product sales, for the three months ended March 31, 2025 and 2024, respectively. The overall 4.0% increase in sales-related allowances and accruals as a percentage of gross product sales was primarily related to accruals as a result of higher chargeback-related allowances from expanded contracting efforts.

Cost of Goods Sold

Cost of goods sold primarily relates to the costs to produce, package and deliver our products to customers. These expenses include labor, raw materials, manufacturing overhead and occupancy costs, depreciation of facilities, royalty payments, quality control and engineering.

The following table provides information regarding our cost of goods sold and gross margin during the periods indicated, including